Maxim Tsypin

Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study

Fumiko Taguchi, Benjamin Solomon, Vanesa Gregorc et al. · JNCI Journal of the National Cancer Institute · 2007 · 315 citations · Full text

Medicine, Oncology, Pharmacology +16

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients

Christine H. Chung, Erin H. Seeley, Heinrich Röder et al. · Cancer Epidemiology Biomarkers & Prevention · 2010 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab

David P. Carbone, J. Stuart Salmon, Dean Billheimer et al. · Lung Cancer · 2009 · 52 citations

Medicine, Oncology, Pharmacology +14

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Chiara Lazzari, Anna Spreafico, Angela Bachi et al. · Journal of Thoracic Oncology · 2011 · 40 citations · Full text

Medicine, Oncology, Pharmacology +12